Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

New England Journal of Medicine

Volumn 345, Issue 22, 2001, Pages 1583-1592

  Brown, B Greg ^a   Zhao, Xue Qiao ^a   Chait, Alan ^a   Fisher, Lloyd D ^a   Cheung, Marian C ^a   Morse, Josh S ^a   Dowdy, Alice A ^a   Marino, Emily K ^a   Bolson, Edward L ^a   Alaupovic, Petar ^b   Frohlich, Jiri ^c   Serafini, Leny ^a   Huss Frechette, Ellen ^a   Wang, Shari ^a   DeAngelis, Debbie ^c   Dodek, Arthur ^c   Albers, John J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SELENIUM; SIMVASTATIN; SLO NIACIN; VITAMIN;

ADULT; ARTERIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ALPHA-TOCOPHEROL; ANTILIPEMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS; ASCORBIC ACID; BETA CAROTENE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY STENOSIS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; NIACIN; SELENIUM; SIMVASTATIN; VITAMIN E;

EID: 0035969564     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011090     Document Type: Article

References (37)

1. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: The Framingham Offspring study
2. The Munster Heart study (PROCAM): Results of follow-up at 8 years
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
5. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
6. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
7. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
8. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
9. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity
10. Lipid altering or antioxidant vitamins for patients with coronary, disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment study design
11. Prediction of coronary heart disease using risk factor categories
12. Dietary guidelines for healthy American adults: A statement for health professionals from the Nutrition Committee, American Heart Association
13. Exercise testing of patients with coronary heart disease: Principles and normal standards for evaluation
14. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
15. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease
16. Quantitative determination of human apolipoprotein C-III by electroimmunoassay
17. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma: Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease
18. Antioxidant vitamin supplementation and lipid peroxidation in smokers
19. Continuous monitoring of in vitro oxidation of human low density lipoprotein
20. A maximum confidence approach for measuring progression and regression of coronary artery disease in clinical trials
21. Quantitative computer techniques for analyzing coronary arteriograms
22. Safety and tolerability of combined niacin plus simvastatin in CAD patients with low-HDLc with or without diabetes
23. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
24. Familial hypoalphalipoproteinemia in premature coronary artery disease
25. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: A Probucol Quantitative Regression Swedish Trial (PQRST) report
26. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
27. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
28. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E, after myocardial infarction: Results of the GISSI-Prevenzione trial
29. Vitamin E supplementation and cardiovascular events in high-risk patients
30. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
31. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase: High density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype
32. Hepatic lipase: New insights from genetic and metabolic studies
33. Quantitative ultrastructural analysis of perifibrous lipid and its association with elastin in nonatherosclerotic human aorta
34. Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience